Pasar al contenido principal

RELEVANCIA FUNCIONAL DE LAS PROTEINAS PROAPOPTOTICAS BAX Y BAK EN LOS TUMORES RABDOIDES TERATOIDES ATIPICOS

PID2021-126426OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE VALLADOLID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Involvement of Bcl-2 Family Proteins in Tetraploidization-Related Senescence

  • Barriuso, Daniel
  • Álvarez-Frutos, Lucía
  • González-Gutiérrez, Lucía
  • Motiño, Omar
  • Kroemer, Guido
  • Palacios-Ramírez, Roberto
  • Senovilla, Laura
The B-cell lymphoma 2 (Bcl-2) family of proteins is the main regulator of apoptosis. However, multiple emerging evidence has revealed that Bcl-2 family proteins are also involved in cellular senescence. On the one hand, the different expression of these proteins determines the entry into senescence. On the other hand, entry into senescence modulates the expression of these proteins, generally conferring resistance to apoptosis. With some exceptions, senescent cells are characterized by the upregulation of antiapoptotic proteins and downregulation of proapoptotic proteins. Under physiological conditions, freshly formed tetraploid cells die by apoptosis due to the tetraploidy checkpoint. However, suppression of Bcl-2 associated x protein (Bax), as well as overexpression of Bcl-2, favors the appearance and survival of tetraploid cells. Furthermore, it is noteworthy that our laboratory has shown that the joint absence of Bax and Bcl-2 antagonist/killer (Bak) favors the entry into senescence of tetraploid cells. Certain microtubule inhibitory chemotherapies, such as taxanes and vinca alkaloids, induce the generation of tetraploid cells. Moreover, the combined use of inhibitors of antiapoptotic proteins of the Bcl-2 family with microtubule inhibitors increases their efficacy. In this review, we aim to shed light on the involvement of the Bcl-2 family of proteins in the senescence program activated after tetraploidization and the possibility of using this knowledge to create a new therapeutic strategy targeting cancer cells., L.S. was supported by the Spanish Agencia Estatal de Investigación, AEI (grant number PID2021-126426OB-I00), the Strategic Program from the Institute of Biomedicine and Molecular Genetics (IBGM) of Valladolid (CCVC8485) and the Internationalization Project of the Unit of Excellence IBGM of Valladolid from the Junta de Castilla y León (CL-EI-2021 IBGM), as well as the “Beatriz Galindo senior” Program from the Spanish Ministry of Universities. G.K. was supported by the Ligue contre le Cancer (équipe labellisée), Agence National de la Recherche (ANR)—Projets blancs, AMMICa US23/CNRS UMS3655, Association pour la recherche sur le cancer (ARC), Cancéropôle Ile-de-France, European Research Council Advanced Investigator Grand “ICD-Cancer”, Fondation pour la Recherche Médicale (FRM), a donation by Elior, Equipex Onco-Pheno-Screen, European Joint Programme on Rare Diseases (EJPRD), European Research Council (ICD-Cancer), European Union Horizon 2020 Projects Oncobiome and Crimson, Fondation Carrefour, Institut National du Cancer (INCa), Institut Universitaire de France, LabEx Immuno-Oncology (ANR-18-IDEX-0001), a Cancer Research ASPIRE Award from the Mark Foundation, the RHU Immunolife, Seerave Foundation, SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE) and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001. D.B. and R.P.-R. were supported by the University of Valladolid. L.G.-G. was supported by the “Margarita Salas” Program from the Spanish Ministry of Universities., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multiomics insights on the onset, progression, and metastatic evolution of breast cancer

  • Álvarez-Frutos, Lucía
  • Barriuso, Daniel
  • Durán, Mercedes
  • Infante, Mar
  • Kroemer, Guido
  • Palacios-Ramírez, Roberto
  • Senovilla, Laura
Breast cancer is the most common malignant neoplasm in women. Despite progress to date, 700,000 women worldwide died of this disease in 2020. Apparently, the prognostic markers currently used in the clinic are not sufficient to determine the most appropriate treatment. For this reason, great efforts have been made in recent years to identify new molecular biomarkers that will allow more precise and personalized therapeutic decisions in both primary and recurrent breast cancers. These molecular biomarkers include genetic and post-transcriptional alterations, changes in protein expression, as well as metabolic, immunological or microbial changes identified by multiple omics technologies (e.g., genomics, epigenomics, transcriptomics, proteomics, glycomics, metabolomics, lipidomics, immunomics and microbiomics). This review summarizes studies based on omics analysis that have identified new biomarkers for diagnosis, patient stratification, differentiation between stages of tumor development (initiation, progression, and metastasis/recurrence), and their relevance for treatment selection. Furthermore, this review highlights the importance of clinical trials based on multiomics studies and the need to advance in this direction in order to establish personalized therapies and prolong disease-free survival of these patients in the future., LS is supported by the Spanish Agencia Estatal de Investigación, AEI (grant number PID2021-126426OB-I00), the Strategic Program from the Institute of Biomedicine and Molecular Genetics (IBGM) of Valladolid (CCVC8485) and the Internationalization Project of the Unit of Excellence IBGM of Valladolid from the Junta de Castilla y León (CL-EI-2021 IBGM), the Institut National du Cancer (INCa, PLBIO2022-093), as well as the “Beatriz Galindo” Program from the Spanish Ministry of Universities. GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; European Research Council Advanced Investigator Grand “ICD-Cancer”, Fondation pour la Recherche Médicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); European Research Council (ICD-Cancer), European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); a Cancer Research ASPIRE Award from the Mark Foundation; the RHU Immunolife; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001. LA-F holds a predoctoral fellowship from the Asociación Española Contra el Cáncer (AECC). DB and RPR are supported by the University of Valladolid., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mineralocorticoid Receptor and Sleep Quality in Chronic Kidney Disease

  • Puente-Aldea, Juan de la
  • López-Llanos, Óscar
  • Horrillo, Daniel
  • Marcos-Sánchez, Hortensia
  • Sanz-Ballesteros, Sandra
  • Franco, Raquel
  • Jaisser, Frederic
  • Senovilla, Laura
  • Palacios-Ramírez, Roberto
The classical function of the mineralocorticoid receptor (MR) is to maintain electrolytic homeostasis and control extracellular volume and blood pressure. The MR is expressed in the central nervous system (CNS) and is involved in the regulation of the hypothalamic–pituitary–adrenal (HPA) axis as well as sleep physiology, playing a role in the non-rapid eye movement (NREM) phase of sleep. Some patients with psychiatric disorders have very poor sleep quality, and a relationship between MR dysregulation and this disorder has been found in them. In addition, the MR is involved in the regulation of the renal peripheral clock. One of the most common comorbidities observed in patients with chronic kidney disease (CKD) is poor sleep quality. Patients with CKD experience sleep disturbances, including reduced sleep duration, sleep fragmentation, and insomnia. To date, no studies have specifically investigated the relationship between MR activation and CKD-associated sleep disturbances. However, in this review, we analyzed the environment that occurs in CKD and proposed two MR-related mechanisms that may be responsible for these sleep disturbances: the circadian clock disruption and the high levels of MR agonist observed in CKD., LS is supported by the Spanish Agencia Estatal de Investigación, AEI, (grant number PID2021-126426OB-I00) and the “Beatriz Galindo senior” Program from the Spanish Ministry of Universities. RPR is supported by the University of Valladolid., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Obesity-Associated Colorectal Cancer

  • González-Gutiérrez, Lucía
  • Motiño, Omar
  • Barriuso, Daniel
  • Puente-Aldea, Juan de la
  • Álvarez-Frutos, Lucía
  • Kroemer, Guido
  • Palacios-Ramírez, Roberto
  • Senovilla, Laura
Colorectal cancer (CRC) affects approximately 2 million people worldwide. Obesity is the major risk factor for CRC. In addition, obesity contributes to a chronic inflammatory stage that enhances tumor progression through the secretion of proinflammatory cytokines. In addition to an increased inflammatory response, obesity-associated cancer presents accrued molecular factors related to cancer characteristics, such as genome instability, sustained cell proliferation, telomere dysfunctions, angiogenesis, and microbial alteration, among others. Despite the evidence accumulated over the last few years, the treatments for obesity-associated CRC do not differ from the CRC treatments in normal-weight individuals. In this review, we summarize the current knowledge on obesity-associated cancer, including its epidemiology, risk factors, molecular factors, and current treatments. Finally, we enumerate possible new therapeutic targets that may improve the conditions of obese CRC patients. Obesity is key for the development of CRC, and treatments resulting in the reversal of obesity should be considered as a strategy for improving antineoplastic CRC therapies., L.S. is supported by the Spanish Agencia Estatal de Investigación, AEI, (grant number PID2021-126426OB-I00); and the “Beatriz Galindo senior” Program from the Spanish Ministry of Universities. L.G.-G. is supported by the “Margarita Salas” Program from the Spanish Ministry of Universities. O.M. is supported by the “Beatriz Galindo junior” Program from the Spanish Ministry of Universities. D.B. and R.P.-R. are supported by the University of Valladolid. L.A.-F. holds a predoctoral fellowship from the Asociación Española Contra el Cáncer (AECC). G.K. is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR-22-CE14-0066 VIVORUSH, ANR-23-CE44-0030 COPPERMAC, ANR-23-R4HC-0006 En-er-LIGHT); Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Joint Programme on Rare Diseases (EJPRD) Wilsonmed; European Research Council Advanced Investigator Award (ERC-2021-ADG, Grant No. 101052444; project acronym: ICD-Cancer, project title: Immunogenic cell death (ICD) in the cancer-immune dialogue); the ERA4 Health Cardinoff Grant Ener-LIGHT; European Union Horizon 2020 research and innovation programmes Oncobiome (grant agreement number: 825410, Project Acronym: ONCOBIOME, Project title: Gut OncoMicrobiome Signatures [GOMS] associated with cancer incidence, prognosis, and prediction of treatment response, Prevalung (grant agreement number 101095604, Project Acronym: PREVALUNG EU, project title: Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception), Neutrocure (grant agreement number 861878: Project Acronym: Neutrocure; project title: Development of “smart” amplifiers of reactive oxygen species specific to aberrant poly-morphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer, and myeloablation); national support managed by the Agence Nationale de la Recherche under the France 2030 programme (reference number 21-ESRE-0028, ESR/Equipex+ Onco-Pheno-Screen); Hevolution Network on Senescence in Aging (reference HF-E Einstein Network); Institut National du Cancer (INCa); Institut Universitaire de France; LabEx Immuno-Oncology ANR-18-IDEX-0001; a Cancer Research ASPIRE Award from the Mark Foundation; PAIR-Obésité INCa_1873, the RHUs Immunolife and LUCA-pi (ANR-21-RHUS-0017 and ANR-23-RHUS-0010, both dedicated to France Relance 2030); Seerave Foundation; SIRIC Cancer Research and Personalized Medicine (CARPEM, SIRIC CARPEM INCa-DGOS-Inserm-ITMO Cancer_18006 supported by Institut National du Cancer, Ministère des Solidarités et de la Santé, and INSERM). This study contributes to the IdEx Université de Paris Cité ANR-18-IDEX-0001., Peer reviewed